Ionis Pharmaceuticals Inc (IONS) Common Stock USD0.001

Sell:$29.69Buy:$29.70$0.03 (0.10%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$29.69
Buy:$29.70
Change:$0.03 (0.10%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$29.69
Buy:$29.70
Change:$0.03 (0.10%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Key people

Brett P. Monia
Chief Executive Officer, Director
Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Joseph T. Baroldi
Executive Vice President, Chief Business Officer
Richard S. Geary
Executive Vice President, Chief Development Officer
Kyle Jenne
Executive Vice President - commercial
Eugene Schneider
Executive Vice President, Chief Clinical Development and Operations Officer
Eric E. Swayze
Executive Vice President - Research
Patrick R. O'Neil
Chief Legal Officer, General Counsel and Corporate Secretary
Joseph Loscalzo
Independent Chairman of the Board
Joseph H. Wender
Lead Independent Director
B. Lynne Parshall
Director
Spencer R. Berthelsen
Independent Director
Allene M. Diaz
Independent Director
Click to see more

Key facts

  • EPIC
    IONS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US4622221004
  • Market cap
    $4.63bn
  • Employees
    1,069
  • Shares in issue
    158.96m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.